Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

NCT04909255 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Sjogren's Syndrome
Overactive Bladder Syndrome

Interventions

DRUG: mirabegron
DRUG: oxybutynin, tolterodine, solifenacin

Sponsor

China Medical University Hospital